Lupin and Zentiva partner to commercialize Certolizumab Pegol biosimilar globally, sharing profits and investing in ...

Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of ...

Lupin and Zentiva announce a license and supply agreement for the commercialization of biosimilar Certolizumab Pegol across ...

Global Pharma major Lupin Limited and Zentiva Group, a pan-European pharmaceutical company, have entered into a license and ...

Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for ...

Lupin & Zentiva ink licensing and supply agreement for commercializing biosimilar Certolizumab Pegol: Our Bureau, Mumbai Wednesday, July 9, 2025, 16:20 Hrs [IST] Global Pharma maj ...

Certolizumab Pegol is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic ...

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...